Livmarli tablets will be available in June through Mirum Access Plus pharmacy.
We expect investors to focus on updates related to Sol-Gel Technologies, Ltd.’s SLGL ability to regain compliance with the recent Nasdaq requirement and other pipeline development activities when it...
Castle Biosciences, Inc. CSTL is scheduled to report fourth-quarter and full-year 2024 results on Feb. 27, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is...
We expect investors to focus on the sales performance of ADMA Biologics’ ADMA portfolio of marketed products and other pipeline updates when it reports fourth-quarter 2024 results.See the Zacks Earnings...
Shares of Mirum Pharmaceuticals MIRM were up 12.1% this week, driven by investor enthusiasm after the company announced encouraging preliminary sales numbers for the fourth quarter and full year 2024,...
Shares of Mirum Pharmaceuticals, Inc. MIRM have rallied 90.9% in the past six months compared with the industry’s increase of just 1.1%.The company’s lead product is Livmarli (maralixibat), an orally...
Mirum Pharmaceuticals, Inc. MIRM incurred a loss of 30 cents per share in third-quarter 2024, much narrower than the Zacks Consensus Estimate of a loss of 45 cents. The company had reported a loss of 57...
Stocks that traded heavily or had substantial price changes on Monday: United States Steel, NIO rise; Masonite, Mirum Pharmaceuticals fall
A mixed trial could hurt a kidney drug's chances of full approval.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for first quarter 2023 and provided a business update.